CombinedError

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 2 clinical trial for treating tumors, which harbor the H3 K27M mutation in glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2 (COVID-19) infection. The company has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Chimerix 

NASDAQ

Free

Chimerix 's Price growth average in the last 3 years of 77.57% is great compared to market average of 9.66%. This indicates CMRX could be a good value stock.

Price growth average in the last 3 years vs Market

Chimerix 's Owned by insiders of 6.98% is modest compared to market average of 8.74%. This indicates CMRX could have a small participation of stakeholders.

Owned by insiders vs Market

Value

Quality

Ownership

Growth

Dividends

is a comprehensive guide for investors seeking income investments. It helps discover stocks with attractive dividend yield trends and growth potential based on historical data.

empowers investors by providing accurate growth forecasts and indicators, enabling them to make proactive choices and build winning portfolios.

reveals confidence through institutional and insider holdings, which help investors understand the dynamics of stock ownership.

assesses a company's operational efficiency, financial health, stability, and growth potential, aiding investment decisions.

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

helps identify undervalued stocks based on fundamentals, ideal for value investors like Warren Buffett.

Performance History

Score Breakdown

Welcome to Stocklytics

Analyst Forecast

Analyst Ratings

Chimerix (CMRX)

Keep an eye on Chimerix

Take Your Investments to a Whole New Level